Weis Holger 4

What Happened

• Holger Weis, Chief Executive Officer of Alaunos Therapeutics, received an award of 7,761 shares of common stock on June 12, 2026. The shares were issued at an effective price of $2.26 per share, for a total value of approximately $17,540. This was an issuance as compensation (not an open-market purchase).

Key Details

• Transaction date and price: 6/12/2026, 7,761 shares at $2.26 each.
• Total value: ~ $17,540.
• Shares owned after transaction: Not specified in the filing.
• Footnote: F1 — shares issued in lieu of net salary (compensation).
• Form 4 filed: 2026-06-17 (filed five days after the transaction date; check filing timeliness against the 2-business-day reporting rule).

Context

• These shares were issued as compensation (salary substitution), which is a routine executive compensation action and does not necessarily reflect a market view. The size of the award is relatively small in dollar terms compared with typical insider trades, so it’s more about payroll/compensation mechanics than a signal of confidence or concern.